Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development

Clinical Chemistry and Laboratory Medicine

Volumn 53, Issue 1, 2015, Pages 95-102

  Asazawa, Hitomi ^a   Kamada, Yoshihiro ^a   Takeda, Yuri ^a   Takamatsu, Shinji ^a   Shinzaki, Shinichiro ^a   Kim, Youkoku ^b   Nezu, Riichiro ^b   Kuzushita, Noriyoshi ^c   Mita, Eiji ^c   Kato, Michio ^c   Miyoshi, Eiji ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA ROSAI HOSPITAL   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

fucosylation; lectin antibody ELISA kit; protein induced by vitamin K antagonist II (PIVKA II); fetoprotein (AFP)

Indexed keywords

ALPHA FETOPROTEIN; ALPHA FETOPROTEIN L3; BIOLOGICAL MARKER; FUCOSYLATED HAPTOGLOBIN; HAPTOGLOBIN; TUMOR MARKER; UNCLASSIFIED DRUG; FUCOSE;

ANGIOGRAPHY; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; EARLY CANCER; EARLY DIAGNOSIS; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; FUCOSYLATION; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; ULTRASOUND; BLOOD; LIVER NEOPLASMS; METABOLISM;

CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; FUCOSE; HAPTOGLOBINS; HUMANS; LIVER NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84916241816     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0427     Document Type: Article

References (20)

1. Miyoshi E, Moriwaki K, Nakagawa T. Biological function of fucosylation in cancer biology. J Biochem 2008;143:725-9.
2. Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, Di Bisceglie AM, et al. Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2009;18:1914-21.
3. Hashimoto S, Asao T, Takahashi J, Yagihashi Y, Nishimura T, Saniabadi AR, et al. alpha1-Acid glycoprotein fucosylation as a marker of carcinoma progression and prognosis. Cancer 2004;101:2825-36.
4. Debruyne EN, Vanderschaeghe D, Van Vlierberghe H, Vanhecke A, Callewaert N, Delanghe JR. Diagnostic value of the hemopexin N-glycan profile in hepatocellular carcinoma patients. Clin Chem 2010;56:823-31.
5. Taketa K. Alpha-fetoprotein: Reevaluation in hepatology. Hepatology 1990;12:1420-32.
6. Breborowicz J, Mackiewicz A, Breborowicz D. Microheterogeneity of alpha-fetoprotein in patient serum as demonstrated by lectin affino-electrophoresis. Scand J Immunol 1981;14:15-20.
7. Taketa K, Izumi M, Ichikawa E. Distinct molecular species of human alpha-fetoprotein due to differential affinities to lectins. Ann N Y Acad Sci 1983;417:61-8.
8. Aoyagi Y. Carbohydrate-based measurements on alphafetoprotein in the early diagnosis of hepatocellular carcinoma. Glycoconj J 1995;12:194-9.
9. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137:110-8.
10. Okuyama N, Ide Y, Nakano M, Nakagawa T, Yamanaka K, Moriwaki K, et al. Fucosylated haptoglobin is a novel marker for pancreatic cancer: A detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer 2006;118:2803-8.
11. Nakano M, Nakagawa T, Ito T, Kitada T, Hijioka T, Kasahara A, et al. Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: A novel approach for the development of tumor markers. Int J Cancer 2008;122:2301-9.
12. Takeda Y, Shinzaki S, Okudo K, Moriwaki K, Murata K, Miyoshi E. Fucosylated haptoglobin is a novel type of cancer biomarker linked to the prognosis after an operation in colorectal cancer. Cancer 2012;118:3036-43.
13. Narisada M, Kawamoto S, Kuwamoto K, Moriwaki K, Nakagawa T, Matsumoto H, et al. Identification of an inducible factor secreted by pancreatic cancer cell lines that stimulates the production of fucosylated haptoglobin in hepatoma cells. Biochem Biophys Res Commun 2008;377:792-6.
14. Matsumoto H, Shinzaki S, Narisada M, Kawamoto S, Kuwamoto K, Moriwaki K, et al. Clinical application of a lectin-Antibody ELISA to measure fucosylated haptoglobin in sera of patients with pancreatic cancer. Clin Chem Lab Med 2010;48:505-12.
15. Kormoczi GF, Saemann MD, Buchta C, Peck-Radosavljevic M, Mayr WR, Schwartz DW, et al. Influence of clinical factors on the haemolysis marker haptoglobin. Eur J Clin Invest 2006;36: 202-9.
16. Kamada Y, Kinoshita N, Tsuchiya Y, Kobayashi K, Fujii H, Terao N, et al. Reevaluation of a lectin antibody ELISA kit for measuring fucosylated haptoglobin in various conditions. Clin Chim Acta 2013;417:48-53.
17. Kagebayashi C, Yamaguchi I, Akinaga A, Kitano H, Yokoyama K, Satomura M, et al. Automated immunoassay system for AFPL3%using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal Biochem 2009;388:306-11.
18. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93.
19. Nakagawa T, Uozumi N, Nakano M, Mizuno-Horikawa Y, Okuyama N, Taguchi T, et al. Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. J Biol Chem 2006;281:29797-806.
20. Nakagawa T, Takeishi S, Kameyama A, Yagi H, Yoshioka T, Moriwaki K, et al. Glycomic analyses of glycoproteins in bile and serum during rat hepatocarcinogenesis. J Proteome Res 2010;9:4888-96.